138 related articles for article (PubMed ID: 11185057)
1. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
5. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
6. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
[TBL] [Abstract][Full Text] [Related]
9. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
10. Use of Regranex gel for diabetic foot ulcers.
Piascik P
J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
[No Abstract] [Full Text] [Related]
11. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
Ladin D
Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
13. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
Papanas N; Maltezos E
Clin Interv Aging; 2008; 3(2):233-40. PubMed ID: 18686746
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
Steed DL
Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
[TBL] [Abstract][Full Text] [Related]
15. Treatment of stingray injury with topical becaplermin gel.
Baldinger PJ
J Am Podiatr Med Assoc; 1999 Oct; 89(10):531-3. PubMed ID: 10546426
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
Ghatnekar O; Persson U; Willis M; Odegaard K
Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
Niezgoda JA; Van Gils CC; Frykberg RG; Hodde JP
Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
[TBL] [Abstract][Full Text] [Related]
19. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
Fruhstorfer B
Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
[No Abstract] [Full Text] [Related]
20. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
Landsman A; Agnew P; Parish L; Joseph R; Galiano RD
J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
